Most recently, CD37 has been demonstrated to inhibit fatty acid metabolism in aggressive B-cell lymphoma through interacting with fatty acid transporter protein 1 (FATP1) in the plasma membrane, and inhibiting the uptake and processing of exogenous palmitate [12]. Here, SLC27A1 is linked to B-cell non-Hodgkin lymphoma.